Clinical trials: Controlled Hypertension
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
This is a phase 2, Multi-center, double-blind, randomized, placebo-controlled study to evaluate the effects of inhaled Iloprost in patients with pulmonary hypertension secondary to COPD.
- Trial name
- NCT01437878
- Testing
- Iloprost
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 2 people
- Sponsor
- Actelion
Diabetes Mellitus, Type 2, Hypertension
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2 diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of…
- Trial name
- NCT01370005
- Testing
- BI 10773
- Where
- 120 sites in United States, Canada and 10 more
- Volunteers
- 825 people
- Sponsor
- Boehringer Ingelheim
Hypertension (HTN)
WEARABLE-BP: Wearable Everyday Automated Readings to Enable Assessment of Blood Pressure Control
The WEARABLE-BP study will evaluate the clinical value of obtaining continual measurements using the Aktiia G1 Optical Blood Pressure Monitoring (OBPM) device in hypertensive patients, compared to using a traditional upper arm…
- Trial name
- WEARABLE-BP (NCT07523269)
- Testing
- Aktiia G1 BP monitor for 12 months, Traditional BP monitor for 6 months / Aktiia G1 BP monitor for 6 months
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Aktiia SA
Hypertension, Chronic Heart Failure
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
The purpose of this study is to assess the tolerability of BIA 5-453 after six multiple rising dose regimens of BIA 5-453.
- Trial name
- NCT02840565
- Testing
- BIA 5-453
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
- Trial name
- GRIPHON (NCT01106014)
- Testing
- Selexipag
- Where
- 182 sites in United States, Argentina and 37 more
- Volunteers
- 1,156 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
This is a Phase 1B, randomized, participant- and investigator-blinded, placebo-controlled, multi-center clinical trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in…
- Trial name
- PAH (NCT03926793)
- Testing
- GB002, Generic Dry Powder Inhaler
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Hypertension
Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients
The primary objective is to evaluate the antihypertensive efficacy of a fixed combination of Irbesartan/HydroChloroThiazide (CoAprovel) in Chinese moderate to severe hypertensive patients.
- Trial name
- NCT00670566
- Testing
- irbesartan/hydrochlorothiazide
- Where
- China
- Volunteers
- 503 people
- Sponsor
- Sanofi
Hypertension
A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension
To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
- Trial name
- NCT00528827
- Testing
- Cardene® I.V.
- Where
- 2 sites in United States
- Sponsor
- Facet Biotech
Glaucoma
Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.
In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks. After 12 weeks, among them, Xalatan administration group are switched to Xalost S or Taflotan-S. Extension study period is 8 weeks.
- Trial name
- NCT04164459
- Testing
- Xalost S, Xalatan, Taflotan-S
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Hypertension
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) 60 mg~120 mg in patients with mild to moderate essential hypertension.
- Trial name
- NCT00922480
- Testing
- Fimasartan, Losartan (Control)
- Volunteers
- 506 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Blood Pressure, High
Registry to Evaluate the ROX COUPLER in Patients With Resistant or Uncontrolled Hypertension
The purpose of this registry is to evaluate the safety and performance of the ROX COUPLER in patients with treatment-resistant or uncontrolled hypertension.
- Conditions
- Hypertension, Blood Pressure, High, Blood Pressure, Resistant, Blood Pressure, Uncontrolled
- Trial name
- NCT01885390
- Testing
- ROX COUPLER
- Where
- 4 sites in Belgium, Netherlands and 1 more
- Volunteers
- 83 people
- Sponsor
- ROX Medical, Inc.
Primary Open-angle Glaucoma, Ocular Hypertension
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
To evaluate the safety and efficacy of Levobetaxolol in Chinese patients with glaucoma.
- Trial name
- NCT02617459
- Testing
- Levobetaxolol eye drops, Betaxolol eye drops
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Hypertension
Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
The purpose of this study was to evaluate the effect of celecoxib on the efficacy and safety of amlodipine besylate in subjects with newly diagnosed hypertension requiring antihypertensive therapy.
- Trial name
- NCT02172040
- Testing
- Over-encapsulated 10 mg amlodipine besylate tablet, Over-encapsulated 200 mg celecoxib capsule
- Where
- 10 sites in United Kingdom
- Volunteers
- 152 people
- Sponsor
- Kitov Pharmaceuticals, Ltd.
Hypertension
A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)
The purpose of this study was to compare the antihypertensive efficacy of different doses of losartan compared to placebo and enalapril, in patients with supine diastolic blood pressure of 100-115 mmHg.
- Trial name
- NCT00882440
- Testing
- losartan potassium, Enalapril
- Volunteers
- 576 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx
This study evaluated the effect of ISIS 757456 (IONIS-AGT-LRx) on plasma angiotensinogen (AGT) and systolic blood pressure (SBP) in uncontrolled hypertensive participants who were on two to three antihypertensive medications.
- Trial name
- NCT04083222
- Testing
- ISIS 757456
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertension
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
- Trial name
- NCT00422461
- Testing
- PF-00489791
- Where
- 20 sites in United States
- Volunteers
- 135 people
- Sponsor
- Pfizer
Hypertension
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
In this study it is intended to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg and the combination of candesartan 32 mg and HCT 12.5…
- Trial name
- NCT00383929
- Testing
- Candesartan cilexetil, Hydrochlorothiazide
- Where
- 132 sites in Denmark, Estonia and 9 more
- Volunteers
- 1,979 people
- Sponsor
- AstraZeneca
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-3 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
- Trial name
- NCT05199129
- Testing
- HCP1904-3, RLD2001-1
- Where
- South Korea
- Volunteers
- 166 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension, Portal
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects with portal hypertension (HVPG greater than or equal to 6 mm Hg) who also…
- Trial name
- NASH-CX (NCT02462967)
- Testing
- GR-MD-02
- Where
- 46 sites in United States
- Volunteers
- 162 people
- Sponsor
- Galectin Therapeutics Inc.
Primary Open Angle Glaucoma
Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty
A prospective, multicenter, randomized, single-masked clinical trial to evaluate the effectiveness outcomes of canaloplasty performed as a standalone procedure with the iTrack microcatheter to the Omni surgical system, and to…
- Trial name
- MAGIC (NCT04769453)
- Testing
- Canaloplasty using the iTrack microcatheter with Healon GV Pro, Canaloplasty using the Omni surgical system with Healon GV Pro, Canaloplasty using the iTrack microcatheter with Healon Pro
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Nova Eye, Inc.